Back

Safety of continuing mineralocorticoid receptor antagonists treatment in patients with heart failure with reduced ejection fraction and severe kidney disease: data from swedish heart failure registry

23 May 2023 (10:10 - 10:19)
Organised by: Logo
Congress Presentation Part of: Pharmacotherapy Pharmacotherapy HFA Premium Access Heart Failure 2023 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Federica Guidetti

Inselspital - University of Bern, Bern (Switzerland)

6 More presentations in this session

Presentation thumbnail
Real-world use of sodium-glucose co-transporter 2 inhibitors in patients with heart failure and reduced ejection fraction: data from the Swedish heart failure registry
Doctor D. Stolfo (Udine, IT)
Abstract Slides Video
Presentation thumbnail
Dapagliflozin reduces loop diuretic requirement over time in patients with heart failure with mildly reduced or preserved ejection fraction in the DELIVER Trial
Doctor S. Chatur (Boston, US)
Abstract Slides Video
Presentation thumbnail
Treatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction results from the EMPULSE trial.
Doctor J. Tromp (Singapore, SG)
Abstract Slides Video
Presentation thumbnail
Mineralocorticoid receptor antagonist initiation during admission is associated with improved outcomes irrespective of ejection fraction in patients with acute heart failure
Ms I. Beldhuis (Groningen, NL)
Abstract Slides Video
Presentation thumbnail
Impact of lower systolic blood pressure on efficacy and safety of sacubitri/valsartan compared to ramipril in patients with acute myocardial infarction: insights from PARADISE-MI trial
Doctor M. Senni (Bergamo, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Pharmacotherapy
Video

The Event

Event poster

Heart Failure 2023

23 May 2023 10:10 CET
You may be interested in
thumbnail
Congress Session
Pharmacotherapy
thumbnail
Congress Presentation
Moving forward with MRAs
thumbnail
Congress Presentation
Non-steroidal mineralocorticoid receptor antagonists

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources